{"doi":"10.1111/all.14310","title":"Inhibition of uric acid or IL‐1β ameliorates respiratory syncytial virus immunopathology and development of asthma","abstract":"BACKGROUND: Respiratory syncytial virus (RSV) affects most infants early in life and is associated with increased asthma risk. The specific mechanism remains unknown. OBJECTIVE: To investigate the role of uric acid (UA) and IL-1β in RSV immunopathology and asthma predisposition. METHODS: Tracheal aspirates from human infants with and without RSV were collected and analyzed for pro-IL-1β mRNA and protein to establish a correlation in human disease. Neonatal mouse models of RSV were employed, wherein mice infected at 6-7 days of life were analyzed at 8 days postinfection, 5 weeks postinfection, or after a chronic cockroach allergen asthma model. A xanthine oxidase inhibitor or IL-1 receptor antagonist was administered during RSV infection. RESULTS: Human tracheal aspirates from RSV-infected infants showed elevated pro-IL-1β mRNA and protein. Inhibition of UA or IL-1β during neonatal murine RSV infection decreased mucus production, reduced cellular infiltrates to the lung (especially ILC2s), and decreased type 2 immune responses. Inhibition of either UA or IL-1β during RSV infection led to chronic reductions in pulmonary immune cell composition and reduced type 2 immune responses and reduced similar responses after challenge with cockroach antigen. CONCLUSIONS: Inhibiting UA and IL-1β during RSV infection ameliorates RSV immunopathology, reduces the consequences of allergen-induced asthma, and presents new therapeutic targets to reduce early-life viral-induced asthma development.","journal":"Allergy","year":2020,"id":93686,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":39,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9608,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":345348,"name":"Carrie‐Anne Malinczak","orcid":"0000-0003-3377-5921","position":1,"is_corresponding":false},{"id":345350,"name":"Shannon K.K. Best","orcid":"0000-0002-3713-0779","position":2,"is_corresponding":false},{"id":290554,"name":"Susan B. Morris","orcid":null,"position":3,"is_corresponding":false},{"id":345351,"name":"Andrew J. Rasky","orcid":"0000-0002-8009-4953","position":4,"is_corresponding":false},{"id":385469,"name":"Catherine Ptaschinski","orcid":"0000-0002-2098-8373","position":5,"is_corresponding":false},{"id":289672,"name":"Nicholas W. Lukacs","orcid":"0000-0003-2403-6481","position":6,"is_corresponding":false},{"id":345347,"name":"Wendy Fonseca","orcid":"0000-0002-8982-4633","position":7,"is_corresponding":false},{"id":345349,"name":"Charles F. Schuler","orcid":"0000-0001-5656-7418","position":0,"is_corresponding":true}],"reference_count":68,"raw_metadata":null,"created_at":"2026-07-18T22:31:34.149524Z","pmid":"32277487","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}